

**2008 Dana Farber Harvard Cancer Center, Renal Cancer Program – Kidney Cancer Association – Survivor Conference Agenda**

8:30 – Breakfast

9:00- 9:15 – Welcome and Introductions – KCA rep and David McDermott, MD

9:15 – 9:45 – Kidney Cancer Overview – David McDermott, MD

Incidence  
Types of RCC  
Risk factors  
Prognostic factors

9:45 – 10:30 – Targeted Therapies for mRCC – Dror Michaelson, MD

Sunitinib (Sutent)  
Sorafenib (Nexavar)  
Temsirolimus (Torisel)  
Bevacizumab (Avastin)

10:30 – 10:45 – Break

10:45 – 11:15 – The role of Immunotherapy for RCC –Daniel Cho, MD

Interleukin-2  
New treatments

11:15- 12:00 – Future directions in the treatment of RCC – Toni Choueiri, MD

Combinations of targeted therapies  
Adjuvant therapy  
Treatment for patients who fail targeted therapies  
Novel Therapies (e.g. axitinib, pazopanib, etc)

12:00 – 12:30 – Lunch

12: 30 – 3:00 – Educational Symposia (rotating)

Supportive Care – symptom/side effect management, nutrition  
Virginia Seery, NP  
Gretchen Chambers RN  
Kara Oliver NP  
Laurie Appleby?  
Mee Young Lee, NP  
Mary Ellen Bowers, RN  
Arlene Hsu RN

Emotional Support  
Frank McCaffrey, LICSW

Weighing Treatment Options

David McDermott MD  
Jonathan Rosenberg, MD  
Others MD/NP Staff